Google Custom Search

Hepatitis B Exacerbation May Occur in Women after Giving Birth

During pregnancy, several alterations in immune function allow mothers to tolerate the genetically different fetus. These changes can potentially influence the status of various diseases.

As reported in the January 2008 Journal of Viral Hepatitis, researchers in the Netherlands investigated the evolution of liver disease during and after pregnancy in women with chronic hepatitis B patients.

Findings

Between 1998 and 2006 at their clinic, 31 chronic hepatitis B surface antigen (HBsAg) positive women had 38 pregnancies.

24 women (63%) were hepatitis B "e" antigen (HBeAg) positive and the rest (37%) were HBeAg negative.

In 13 pregnancies (34%), the women started taking lamivudine (Epivir-HBV) during the last trimester to lower HBV DNA levels and reduce the risk of vertical transmission to their infants.

In 17 of 38 pregnancies (45%), a significant increase in liver disease activity was observed after delivery, defined as a 3-fold increase in alanine aminotransferase (ALT) within 6 months after giving birth.

Among women treated with lamivudine during the last trimester, 8 of 13 women (62%) still experienced such exacerbations.

The median maximal ALT elevation in these exacerbations was 4.0 times the upper limited of normal (ULN); none led to decompensated liver disease.

It was not possible to predict during pregnancy which women would experience liver disease exacerbations on the basis of HBV DNA level, ALT level, HBeAg status, or any other characteristic.


Conclusion

In conclusion, the authors wrote, "a significant increase in liver inflammation occurs often after pregnancy."

"This may be due to a reactivation of the immune system after delivery," they suggested. "Based on our data, we recommend monitoring closely and if necessary treating women with chronic HBV shortly after delivery."

01/25/08

Reference
MJ Ter Borg, WF Leemans, RA de Man, and others. Exacerbation of chronic hepatitis B infection after delivery. Journal of Viral Hepatitis 15(1): 37-41. January 2008.

Hepatitis B Main Section

Hepatitis B FDA-approved Treatments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved
HBV Treatments
Baraclude  (entecavir)
Epivir-HBV
   (lamivudine; 3TC)
Intron A   (interferon alfa-2b)

Hepsera   (adefovir dipivoxil)
Pegasys
  (peginterferon alfa-2a)
Tyzeka   
(telbivudine)